E
Overview With major advancements in its drug pipeline over the last two years, Synthetic Biologics (SYN) has propelled itself onto the radar of retail investors, philanthropists and major institutions. Only a year ago, Synthetic’s average share volume stagnated around 50,000 in what seemed to be a lack of awareness on Wall Street. This year, however,…